Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

This is phase III randomized, multicenter study adding or not intra-venous Liposomal Trasncrocetin (L-TC) to hypofractionated radiotherapy and concomitant Temozolomide followed by adjuvant Temozolomide in patients with histologically confirmed diagnosis of glioblastoma (GBM).

NCT Number	NCT06477939
Lead Sponsor	Institut de cancérologie Strasbourg Europe Collaborators: LEAF4Life, Inc.
Conditions	Glioblastoma
Enrollment	554 participants
Start Date	2025-01-01
Primary Completion	2032-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-06-27